Table 4.

Nine responders in Dose Escalation Phase (n=24)

ID #	Age	Diagnosis	Stage of Disease	Cytogenetic Risk Group	No. Prior Regimens	Dose BEL	±No. Cycles	Best Responses	Time to Initial Response (days)	Response Duration (days)
2	49	AML	Relapsed	Intermediate	5§	150	9	HI-N	102	147
3	75	CMML-1	Refractory	Favorable	1	150	64	PR	27	1860
9	54	MDS-RCMD	Relapsed	Favorable	4§*	300	11	HI-P	28	279
13	56	AML	Relapsed	Unfavorable	2§	300	4	HI-N	59	41
14	67	AML	Refractory	Intermediate	2	300	6	CR^	49	239
15	67	PMF	Refractory	Intermediate	1*	1000	2	HI-P	21	35
17	70	MDS-RAEB-1	Relapsed	Unfavorable	2§	1000	6	HI-P	86	42
22	76	t-MN	Prev. untreated	Unfavorable	0	1000	4	CR^	21	399
24	68	MDS-RAEB-2	Prev. untreated	Favorable	1	1000	15	CR^	245	534

^*Prior therapy included hypomethylating agent

^§Prior therapy included allogeneic stem cell transplant

^±Number of cycles administered

^{^}Response was ongoing at the time of discontinuation of study treatment; HI-N, HI-P denote hematologic improvement in neutrophils or platelets